

As part of its testing in women's health, TriCore now offers Primary HPV Screening. Interim guidelines for Primary HPV Screening are available from the professional societies of the American Society of Colposcopy and Cervical Pathology (ASCCP | [www.asccp.org](http://www.asccp.org)) and the Society of Gynecologic Oncology (SGO | [www.sgo.org](http://www.sgo.org)).

For all high risk HPV testing (HR-HPV), TriCore utilizes the Roche Cobas 4800 HPV test. This is a HR-HPV test specified by the FDA for Primary HPV Screening in patients 25 years and older. Specimens for this test can be collected in ThinPrep collection media (PreservCyt) or SurePath collection media. TriCore clients may select Primary HPV Screening from the test options on TriCore's Pap requisition form. To distinguish this test from other Pap tests with HR-HPV (co-testing and reflex HPV testing), the Primary HPV Screening test option is found under additional testing on the requisition.

With a test selection of Primary HPV Screening, the ASCCP interim guidelines algorithm will be used as follows:

- 1. POSITIVE FOR HPV 16 OR HPV 18:** No further testing will be performed. Following the ASCCP guidelines, patients with this test result should be considered for immediate colposcopy.
- 2. HIGH RISK-HPV POSITIVE, NOT HPV 16 OR HPV 18:** Specimens will receive automatic reflex Pap testing. This does not require a separate reflex test order or request of a separate Pap test. As per ASCCP guidelines, patients with this result should be considered for immediate colposcopy if the concurrent Pap cytology is abnormal with diagnoses of ASCUS or above.
- 3. NEGATIVE FOR ALL HIGH RISK-HPV TYPES:** No further testing will be performed. Patients may continue their routine screening.

Final test results for Primary HPV Screening will be reported as is currently done for all other HPV testing. Results for reflex Pap tests from #2 above are reported in a separate Gyn Cytology (Pap) report.

For any questions, please contact TriCore's Medical Director of Cytopathology, Dr. Nancy Joste at (505) 938-8800 or TriCore's Scientific Director of Infectious Disease, Dr. Karissa Culbreath at (505) 938-8461.